Dr. Andrew Zhu, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Mem Sloan Kettering Cancer Center

  Residency Hospital

• University Of Mn Med School

  Residency Hospital

• Yale New Haven Hospital

  Residency Hospital

• Beijing Med University China

  Medical School, 1982

• English

• Chinese

• CXCR4 inhibition in tumor microenvironment facilitates anti-PD-1 immunotherapy in sorafenib-treated HCC in mice, 2015-03-20

• Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma, 2011-02-08

• YAP inhibition restores hepatocyte differentiation in advanced HCC leading to tumor regression, 2015-03-12

• Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic Monotherapy, 2015-09-14

• Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC-dependence in intrahepatic cholangiocarcinoma, 2016-05-26

• Differential Association between Circulating Lymphocyte Populations with Outcome after Radiotherapy in Subtypes of Liver Cancer, 2018-04-17

• A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors, 2022-06-02

• Hepatobiliary Cancers, Version 1.2017 Featured Updates to the NCCN Guidelines, 2017-06-26

• Imbalance and Gait Disturbance from Tyrosine Kinase Inhibition in Hepatocellular Cancer, 2012-07-10

• Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances, 2019-03-25

• Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities, 2020-11-05

• Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis, 2009-03-16

• Obesity/type 2 diabetes-associated liver tumors are sensitive to Cyclin D1 deficiency, 2020-06-30

• Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study, 2013-01-29

• Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer, 2015-02-19

• Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets, 2014-06-03

• Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma, 2016-12-29

• Integrative Genomic Analysis of Cholangiocarcinoma Identifies DistinctIDH-Mutant Molecular Profiles, 2017-03-14

• Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers, 2020-01-15

• Phase II study of pemetrexed in patients with advanced neuroendocrine tumors, 2010-02-04

• Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study, 2018-05-29

• Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis, 2016-10-20

• Metabolic Syndrome and Hepatocellular Carcinoma: Two Growing Epidemics with a Potential Link, 2009-12-15

• High lung shunt fraction in colorectal liver tumors is associated with distant metastasis and decreased survival, 2014-07-30

• Mutant IDH inhibits HNF4a to block hepatocyte differentiation and promote biliary cancer, 2014-07-02

• Phase I Study of Pasireotide (SOM 230) and Everolimus (RAD001) in Advanced Neuroendocrine Tumors, 2012-09-14

• A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma (HCC), 2018-09-06

• PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma, 2015-09-15

• Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies From Patients With Liver Disease, 2018-09-13

• Surgical placement of biological mesh spacers to displace bowel away from unresectable liver tumors followed by delivery of dose-intense radiation therapy, 2013-08-29

• TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma, 2019-05-20

• An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis, 2015-07-23

• REVIEW | New horizons for precision medicine in biliary tract cancers, 2017-08-17

• A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer, 2013-10-02

• The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets, 2016-04-18

• Dual PD-1 and VEGFR-2 blockade promotes vascular normalization and enhances anti-tumor immune responses in HCC, 2019-10-14

• Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial, 2020-02-27

• Phase 1/2 Study of Everolimus in Advanced Hepatocellular Carcinoma, 2011-04-27

• Targeting insulin-like growth factor axis in hepatocellular carcinoma, 2011-07-05

• Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis, 2018-05-17

• Recurrence after operative management of intrahepatic cholangiocarcinoma, 2013-03-15

• Mutational Analysis and Clinical Correlation of Metastatic Colorectal Cancer, 2014-02-05

• Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer, 2012-06-12

• Radiation Therapy Enhances Immunotherapy Response in Microsatellite-stable Colorectal and Pancreatic Adenocarcinoma in a Phase II Trial, 2021-11-18

• A Prospective, Phase I/II Study of Everolimus and Temozolomide in Patients with Advanced Pancreatic Neuroendocrine Tumor, 2013-06-03

• Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage?, 2018-01-30

• Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma, 2014-01-29

• Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors, 2017-03-09

• Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy, 2018-10-18

• Ivosidenib inIDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study, 2020-05-13

• KrasG12Dand p53 mutation cause primary intra-hepatic cholangiocarcinoma, 2012-01-20

• Integrative Genomic Analysis of Cholangiocarcinoma Identifies DistinctIDH-Mutant Molecular Profiles, 2017-06-27

• The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology, 2014-12-18

• Hepatocellular Carcinoma: Can Circulating Tumor Cells and Radiogenomics Deliver Personalized Care?, 2014-08-14

• Predictors of Adjuvant Treatment and Survival in Patients with Intrahepatic Cholangiocarcinoma Who Undergo Resection, 2019-03-04

• A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma, 2014-05-24

• Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy, 2013-07-10

• EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive cholangiocarcinoma, 2022-05-02

• Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions, 2014-09-26

• Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1a/CXCR4 axis and Gr-1+ myeloid cell infiltration in mice, 2014-02-18

• Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value, 2010-09-15

• Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers, 2019-09-09

• Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab, 2021-02-03

• Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?, 2009-08-24

• Mutational and Clinical Predictors of Pathologic Complete Response in the Treatment of Locally Advanced Rectal Cancer, 2015-02-20